Efficacy and safety of daratumumab in multiresistant immune‐mediated thrombotic thrombocytopenic purpura

Summary The immunosuppressive treatment of immune‐mediated thrombotic thrombocytopenic purpura (iTTP) in patients with intolerance or refractoriness to the B‐cell depleting monoclonal antibody rituximab remains debated. Daratumumab, a plasma cell‐directed monoclonal antibody targeting CD38, represen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2024-11, Vol.205 (5), p.1951-1958
Hauptverfasser:	Weisinger, Julia, Bouzid, Raïda, Ranta, Dana, Woaye‐Hune, Pascal, Cohen‐Aubart, Fleur, Gaible, Clotilde, Marjanovic, Zora, Corre, Elise, Joly, Anne‐Christine, Baylatry, Minh‐Tam, Joly, Berangère S., Veyradier, Agnès, Coppo, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	ADAM protein ADAMTS13 ADAMTS13 Protein Adult Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use CD38 antigen daratumumab Female Humans Intolerance Male Middle Aged Monoclonal antibodies Patients prognosis Purpura Purpura, Thrombotic Thrombocytopenic - drug therapy relapse Rituximab Rituximab - adverse effects Rituximab - therapeutic use Thrombocytopenic purpura Thrombospondin Thrombotic thrombocytopenic purpura Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!